The 2017-2018 flu season has been worse than normal, with an increase of influenza-like cases and deaths, and researchers are examining why this could be and how to increase vaccine effectiveness in the coming years. This effort includes examining the circulating influenza strains and trying to understand how these match with the predictions made months ago when the yearly influenza vaccine was designed. Circulating strains this flu season include influenza A H3N2 (a H3N2 strain caused the 1968 influenza pandemic), influenza A H1N1pdm09 (the pandemic strain from the 2009 season that is still around), and influenza B. Even though influenza is a relatively small virus whose genome is contained on 8 RNA regions that encode 11 proteins, it evolves rapidly, and these new mutations can spread as new infectious strains disseminate within the population. This is a challenge in creating the annual influenza vaccine, as the vaccine needs to elicit an immune response to some part of the influenza virus that is fairly invariable. Ideally, we would have a single universal vaccine, but this has been a challenging goal to meet because of differences between strains of influenza virus. Instead, each year the World Health Organization (WHO) coordinates surveillance and makes recommendations as to which strains should be included in vaccine preparations.
From the selected strains, vaccines are created to induce the generation of antibodies specific for hemagglutinin, a protein on the surface of influenza that is critical for viral adhesion to host cells. Roughly, hemagglutinin is a spikeshaped protein coming out of the viral capsid with a globular head. Most hemagglutinin-specific antibodies recognize the head, specifically to antigenic site B, but the head is highly mutable and mutations can prevent recognition by the immune system. Moreover, changes can also occur within the viral strains used to create the influenza vaccines within chicken eggs, such that the vaccine antigen does not match that found in the circulating viral strain. For example, to ensure that the 2016-2017 influenza vaccine better matched circulating H3N2 viruses, a clade 3C.2 H3N2 virus was added to the vaccine to replace a H3N2 virus of the 3C.1 hemagglutinin clade. However, the egg-adapted 3C.2a vaccine strain lacks a glycosylation site on the antigenic site B of the hemagglutinin head that is found in H3N2 viruses circulating within humans (Lin et al., 2017) . This mismatch between the egg-adapted vaccine strain and circulating strains could then have implications for vaccine efficacy.
Prompted by low vaccine efficacy in 2016-2017, Zost et al. (2017) examined this glycosylation site further. Circulating H3N2 viruses were found to primarily have threonine (T) at position 160 of hemagglutinin instead of lysine (K), but these strains grew poorly in chicken eggs and the egg-adapted H3N2 strain contains a reversion mutant back to lysine. Zost et al. found that T160 and K160 are antigenically distinct and that antibodies created in ferrets as well as in humans to egg-adapted H3N2 poorly recognize and neutralize circulating H3N2 strains, influencing the effectiveness of the seasonal vaccine. Alternatives to egg-based technology for influenza vaccines exist, including cell-based alternatives or baculovirus systems. Zost et al. (2017) found that Flublok (derived from antigens created in insect cells) did not create an antibody response that was higher but did create a response that was more efficient at recognizing T160 hemagglutinin in circulating H3N2 strains. This work highlights the potential importance of expanding the use of alternative ways of mass producing influenza antigens for vaccines beyond egg-based strategies, since egg-adapted strains can impair influenza vaccine effectiveness. Cell-based flu vaccines are approved for use in several European countries, and the US FDA has approved the use of one cell-based flu vaccine, but existing facilities for egg-based vaccine production would need to be completely rebuilt to move away from egg-based vaccines.
Another way to potentially improve influenza vaccine design is by making mutations within influenza strains to attenuate the virus and increase the immune response. The type I interferon (IFN) system is at the center of the innate immune response against viruses, and viruses have responded with many strategies to get around IFN (García-Sastre, 2017). While multiple modulators and suppressors of IFN are helpful for a virus during pathogenesis, they increase the difficulty of vaccine design because the ideal vaccine strain would induce a rapid and strong immune response, while a vaccine strain that modulates the initial interferon response might dampen subsequent immune responses to that pathogen. In influenza virus, the most well-characterized IFN modulator is non-structural protein NS1, but other modulators of interferon exist and Du et al. (2018) designed a quantitative high-throughput genomics method to systematically identify point mutations that modulate IFN in the genome of influenza A. Using this information about mutations that confer IFN sensitivity and lead to IFN induction, they created the HIS virus strain for vaccination with eight IFN-sensitive mutations that had increased IFN sensitivity and yielded greater in vitro induction of IFN. When the HIS strain was tested in mice and ferrets, it had reduced replication and growth and transiently increased expression of IFN and IFN-stimulated genes, which would both be good qualities for a vaccine strain, limiting damage while stimulating an immune response. When HIS was used to vaccinate mice and ferrets, it induced a robust humoral and cellular immune response and protected against three different influenza A strains, making this a valuable potential strategy. This unbiased technique holds promise for improving strains for vaccinations for other pathogens in addition to influenza.
While efforts to anticipate seasonal influenza strains and produce well-targeted and effective vaccines must continue, the ultimate quest is for a universal influenza vaccine that could be used from year to year. This type of vaccine would rely on conserved sequences from influenza to create antigens that would be able to broadly recognize and neutralize a wide set of influenza strains. In one step toward this goal, Deng et al. (2018) used a double-layered protein nanoparticle approach. Within the core of the protein nanoparticles, a tetramer protein of the influenza matrix protein 2 ectodomain (M2e) was included. M2e can cause a weak-antibody response that fades over time, but it is conserved across influenza strains. The soluble tetramer protein that Deng et al. created included M2e from human, swine, avian, and domestic fowl consensus sequences. Coating the core of the nanoparticles were headless hemagglutinin sequences from the hemagglutinin stalk and hemagglutinin HA2 ectodomain taken from either H1N1 or H3N2 strains. While the head of hemagglutinin is mutable, the spikey stalk of hemagglutinin is more conserved. Vaccination of mice with the protein nanoparticles yielded robust immune responses through antibody-dependent cellular cytotoxicity and antibodydependent cell phagocytosis as well as leading to increased survival when the mice were infected with a range of influenza A strains including H1N1 and H3N2 as well as avian strains H5N1 and H7N9. These latter two are of interest given concerns about pandemics that could arise if avian strains begin broadly circulating in humans. The initial positive indications mark this protein nanoparticle strategy as a promising vaccine strategy for influenza and other pathogens, and because it does not require refrigeration it may also offer a better option for widespread transportation and distribution of vaccines to remote and low-income settings.
These three studies point to three slightly different directions for how we think about vaccine design and creation. All three versions of the future of influenza vaccine design are worthwhile to expand on as a way to improve upon vaccine design as we continue to work toward a universal influenza vaccine. Promisingly, there are Phase 1 and Phase 2 clinical trials of universal influenza vaccines. Eventually, we will be able to pin down the moving target of influenza.
